To provide for the mandatory recall of adulterated or misbranded drugs.

HR 759, HR 5740, S 882, S 3690 - regarding the manufacturing and importation of OTC drugs and the mandatory recall authority of the FDA.

Client expense: $715,571 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Office of Natl Drug Control Policy (NDCP), SENATE, Treasury, Dept of

HR 759 Food and Drug Administration Globalization Act of 2009; S. 882 The Drug and Device Accountability Act of 2009; S. 882 The Drug and Device Accountability Act of 2009; H.R.5740, To provide for the mandatory recall of adulterated or misbranded drugs.

Client expense: Not reported · Firm income: $65,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medical Research Antibiotic Resistance issues P.L. 111-148 Patient Protection and Affordable Care Act (PPACA) - funding of PPACA programs and provisions P.L. 111-152 Health Care and Education Reconciliation Act of 2010 PDUFA Reauthorization - The Prescription Drug User Fee Act is due for reauthorization in 2012 and discussions in anticipation of that reauthorization have begun H.R. 5712 Health Care Technical Corrections - This bill would repeal a provision of the health care reform bill that would extend debarring to all parts of a corporate family when any part of that corporate family settles an investigation of misconduct with the government HR 759 Food and Drug Administration Globalization Act of 2009 S. 882 The Drug and Device Accountability Act of 2009 H.R.5740 - To provide for the mandatory recall of adulterated or misbranded drugs S. 369 Preserve Access to Affordable Generics Act H.R. 1706 Protecting Consumer Access to Generic Drugs Act H.R. 573 Fair Prescription Drug Competition Act S. 501 Fair Prescription Drug Competition Act H.R. 6331 Generating Antibiotic Incentives Now Act of 2010 H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions) - changes to the 340B Drug Discount Program. S. 11 To restore the application of the 340B drug discount program to orphan drugs with respect to childrens hospitals

Client expense: $220,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)